SUMMARY In a prospective study we used phenobarbitone to treat 13 new patients with epilepsy (eight adults and five children). Full seizure control was achieved in 11 patients and poor compliance was documented in one of the remaining two patients (in both of whom seizures were reduced by over 50%). Doses sufficient to give mean steady state plasma levels of more than 43 ,umol/l (10 ,ug/ml) appeared to be associated with better seizure control than lower doses. No serious side effects were observed.
(10-20 tLg/ml),' 66-122 ,umol/l (15-40 ug/ml),2 and 43-302 ,tmol/l ,ug/ml).3 These figures have been based on reports that a mean level of 43 ,tmol/l (10 ug/ml) reduced the incidence of paroxysmal activity in the EEG by 90%,4 that a level of 66 ,umol/l (15 ,ug/ml) prevents febrile convulsions,5 and from retrospective observations in well-controlled patients, rather than prospective studies correlating blood levels with seizure control in epilepsy.
We have studied the efficacy of phenobarbitone when it is used alone in newly diagnosed epilepsy. In addition, by selecting an initial dose which gave plasma levels at the lower end of the range(s) which have been suggested as effective, and monitoring levels frequently, we have attempted to determine the optimum dosage and plasma levels of phenobarbitone for this type of patient. When we began this investigation there was no published study of any anticonvulsant in previously untreated patients with epilepsy. This deficiency has since been made good in the case of phenytoin and carbamazepine. 6 7 Patients and methods In our protocol we chose an initial dose range of 1-0-15 mg/kg for adult patients and 15-3-0 mg/kg for children. One adult was given a higher initial dosage (2 mg/kg) in error, but we decided not to reduce this. The patients were seen one week and three weeks after commencing treatment. Subsequently they were seen monthly until 365 the end of the ninth month and three-monthly thereafter. At each visit the occurrence of seizures or side effects of treatment were noted and blood was drawn for determination of plasma phenobarbitone by GLC, using the method of Rogers et al. 8 Where any patient's seizures continued after treatment began (allowing time for steady state plasma levels to be attained) the dosage of phenobarbitone was increased. At the time of assessment the mean duration of follow up was 11 months (range 8-13 months). All our patients took phenobarbitone tablets, in two or three devided doses each day.
Results
Seizure control Of the 13 patients treated, 11 became free of seizures during the period of follow-up, and two had a marked (>50%) reduction in seizures.
Nine of the 11 who became seizure-free had no further seizures after treatment was initiated. Two patients (nos 10 and 11) had further seizures while on their initial dose of phenobarbitone, but had no further seizures during a long period (>6 months in both cases) using a slightly higher dosage. Both the patients with a >50% reduction in seizures had frequent attacks (13 in six months and six in six months) before treatment. One of success rate of 85-90% can be obtained with monotherapy, using phenobarbitone, phenytoin,679 or carbamazepine.0 7 10 We cannot claim to have defined clearly a figure for the lower end of the range of plasma phenobarbitone levels which will provide full suppression of seizures in newly diagnosed patients. It may be that, as is the case with phenytoin and carbamazepine,6 7 910 blood levels well below those which are usually optimum in severe and longstanding epilepsy may be consistent with full control in many new patients. However, we note that of nine patients who had mean plasma levels of 48 jtmol/l or greater following the introduction of treatment, only one had any further seizures. On the other hand three of the four patients with mean plasma levels less than 44 jumol/l on their initial dose had further seizures. Furthermore two of these three later became free of seizures following a small increase in dosage (and plasma levels), while in the remaining patient adequate levels were not attained, owing to poor compliance. We would now recommend an initial dosage of phenobarbitone sufficient to produce steady state levels in the range 50-65 ,umol/l. This would be approximately 1*5 mg/kg for an adult and between 2-5 and 3-0 mg/kg in the child over 6 years.
Our results are in accord with previous observations on the relationship of plasma phenobarbitone levels to dosage in both adults" 12 and children. ' From an examination of the literature we conclude that the efficacy of phenobarbitone in complex partial (temporal lobe) seizures has not been adequately studied. As we only studied four patients with this type of epilepsy we cannot reach any firm conclusions, but we are forced to question the previous view that temporal lobe seizures "do not respond to and may be made worse by phenobarbitone.""1 Our total number of patients was small and most of them had mild epilepsy. Relatively low doses of phenobarbitone were effective for these new patients and it is probably because of this that we did not encounter serious side effects. One of us is studying further patients, including those with more severe epilepsy, in an attempt to define an optimum range of phenobarbitone dosage and plasma levels in epilepsy. 
